May 05, 2021
Company to partner with Cipla for pan-India distribution Roche India on Wednesday received Emergency User Authorisation (EUA) from regulator - Central Drugs Standards Control Organisation (CDSCO) for antibody cocktail (Casirivimab and Imdevimab) to be used for treatment of mild to moderate Covid-19 in adults and kids aged 12 years or older in India.
The approval was based on the data filed for the EUA in the United States and the scientific opinion of the Committee for Medicinal Products for Human Use (CHMP) in the European Union.
The EUA will enable Roche to import the globally manufactured product batches to India. Company will market and distribute these products in India through its strategic partner Cipla Limited.